ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center, says it will spend $1 billion over the next 4 years to develop new drugs, diagnostics, and medical devices. The investment includes a previously announced $200 million to support an immunotherapy venture with the University of Pittsburgh. In the past 2 years, UPMC Enterprises has launched five companies and invested in another, Werewolf Therapeutics. In addition to immunotherapy, it will target respiratory disease and neuroinflammation, among other illnesses.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X